Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 21, 2013; 19(47): 8924-8928
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8924
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8924
Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients
Alessandra Mangia, Leonardo Mottola, Rosanna Santoro, Liver Unit-IRCCS, “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, 71013 FG, Italy
Author contributions: All authors contributed to the manuscript.
Correspondence to: Alessandra Mangia, MD, Liver Unit-IRCCS, “Casa Sollievo della Sofferenza”, Viale Cappuccini 1, San Giovanni Rotondo, 71013 FG, Italy. a.mangia@tin.it
Telephone: +39-882-416375 Fax: +39-882-416271
Received: October 2, 2013
Revised: October 30, 2013
Accepted: November 28, 2013
Published online: December 21, 2013
Processing time: 110 Days and 15.4 Hours
Revised: October 30, 2013
Accepted: November 28, 2013
Published online: December 21, 2013
Processing time: 110 Days and 15.4 Hours
Core Tip
Core tip: The clinical relevance of interleukin 28B genotyping in patients with hepatitis C virus genotype 2 and 3 infection is debated. In this critical analysis of studies performed so far, it was shown that this genetic tool may help in optimizing treatment of genotype 3 patients, whilst it plays a marginal role in genotype 2 infected patients management.